Advertisement

Reactions Weekly

, Volume 1786, Issue 1, pp 130–130 | Cite as

Nivolumab

Rejection of a liver allograft: case report
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

A 73-year-old man experienced acute cellular rejection (ACR) of liver leading to chronic cellular rejection mediated liver graft loss following treatment with nivolumab for non-melanoma skin cancers and a conjunctival squamous cell carcinoma [route and dosage not stated].

The man had undergone a deceased donor liver transplantation 12 years previously due to cryptogenic cirrhosis complicated by hepatocellular carcinoma, was hospitalised for abnormal liver tests. Since the transplantation, he had over 25 skin lesions diagnosed as non-melanoma skin cancer. In 2016, he developed conjunctival lesions that were subsequently removed and confirmed to be squamous cell carcinoma. In 2017, another fungating tumour was found to involve the left scalp, and he underwent wide local excision,...

Reference

  1. Lee BT, et al. Checkpoint Inhibitor-Induced Rejection of a Liver Allograft: A Combination of Acute T Cell-Mediated and Antibody-Mediated Rejection. Liver Transplantation 25: 1845-1848, No. 12, Dec 2019. Available from: URL: http://doi.org/10.1002/lt.25622 CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2020

Personalised recommendations